MAPT and Mental deterioration: The current findings indicate that an early, CU-D stage is associated with subclinical cognitive decline that is detectable in late middle-age, and that such declines are associated with increased prevalence of elevated amyloid and tau PET biomarkers and increased risk of future clinical impairment.